Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM5JJ83)

Drug Name

Varespladib Drug Info

Synonyms

Varespladib; 172732-68-2; LY315920; Varespladib (LY315920); LY-315920; S-5920; VAREPLADIB; 2Q3P98DATH; ({3-[amino(oxo)acetyl]-1-benzyl-2-ethyl-1H-indol-4-yl}oxy)acetic acid; 2-(1-benzyl-2-ethyl-3-oxamoylindol-4-yl)oxyacetic acid; CHEMBL148674; S 5920; 2-((3-(2-amino-2-oxoacetyl)-1-benzyl-2-ethyl-1H-indol-4-yl)oxy)acetic acid; 2-[[3-(2-Amino-2-oxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid; 2-(3-(2-amino-2-oxoacetyl)-1-benzyl-2-ethyl-1H-indol-4-yloxy)acetic acid; SMR004701444; Varespladib [INN]; Varespladib [USAN]; Varespladib [USAN:INN]; UNII-2Q3P98DATH; varespladibum; ((3-(AMINO(OXO)ACETYL)-1-BENZYL-2-ETHYL-1H-INDOL-4-YL)OXY)ACETIC ACID; VRD; VARESPLADIB [MI]; Varespladib (USAN/INN); SCHEMBL26726; VARESPLADIB [WHO-DD]; MLS006010414; MLS006010980; varespladib methyl (A-002); varespladib sodium (A-001); LY 315920 (Varespladib); GTPL9657; DTXSID50169378; EX-A153; CHEBI:189668; BCPP000175; HMS3654E04; HMS3744O03; AMY19698; BCP01854; BDBM50055366; MFCD00944812; s1110; ((3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl)oxy)acetate; AKOS015842901; compound 6m [PMID: 8978844]; BCP9000883; CCG-268404; DB11909; EX-8676; SB16690; NCGC00346491-01; NCGC00346491-02; NCGC00346491-08; NCGC00346491-12; AC-32931; AS-16956; HY-13402; A-001; FT-0659937; SW219559-1; A25228; D08107; EN300-144829; J-010846; Q7915613; BRD-K09711437-001-01-9; Z1721255146; (3-Aminooxalyl-1-benzyl-2-ethyl-1H-indol-4-yloxy)-acetic acid; 2-[2-ethyl-3-oxamoyl-1-(phenylmethyl)indol-4-yl]oxyethanoic acid; ((3-(Aminooxoacetyl)-1-benzyl-2-ethyl-1H-indol-4-yl)oxy)acetic acid; (3-Aminooxalyl-1-benzyl-2-ethyl-2,3-dihydro-1H-indol-4-yloxy)-acetic acid; 2-{[1-benzyl-3-(carbamoylcarbonyl)-2-ethyl-1H-indol-4-yl]oxy}acetic acid; ACETIC ACID, ((3-(AMINOOXOACETYL)-2-ETHYL-1-(PHENYLMETHYL)-1H-INDOL-4-YL)OXY)-; Acetic acid, ((3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl)oxy)-,; LY 315920; Varespladib; 2-[[3-(2-Amino-2-oxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic aci

Indication

Disease Entry	ICD 11	Status	REF
Snakebite	N.A.	Phase 2	[1]

Cross-matching ID

PubChem CID: 155815
TTD Drug ID: DM5JJ83

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Phospholipase A2 (PLA2G1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cholic Acid	DM7OKQV	Cholelithiasis	DC11	Approved	[3]
Miltefosine	DMND304	Chronic urticaria		Approved	[4]
Clocortolone	DM9ZMQH	Exanthem		Approved	[5]
Clobetasol	DMUXP52	Rosacea	ED90.0	Approved	[6]
Diflorasone	DMI9PRJ	Exanthem		Approved	[7]
AllerB	DM78DOT	Allergy	4A80-4A85	Phase 2b	[8]
URSOLIC ACID	DM4SOAW	Metabolic syndrome x	5C50-5D2Z	Phase 2	[9]
MANOALIDE	DMB4A8I	Arthritis	FA20	Phase 2	[10]
MRX-4	DMQZWYE	Allergic rhinitis	CA08.0	Phase 2	[11]
MRX-6	DMLVQKF	Contact dermatitis	EK0Z	Phase 2	[12]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Phospholipase A2 (PLA2G1B)	TT9V5JH	PA21B_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT05717062) Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Intravenous Varespladib Followed by Oral Varespladib in Addition to Standard of Care in Subjects Bitten by Venomous Snakes. U.S.National Institutes of Health.
2	Varespladib in the Treatment of Snakebite Envenoming: Development History and Preclinical Evidence Supporting Advancement to Clinical Trials in Patients Bitten by Venomous Snakes. Toxins (Basel). 2022 Nov 11;14(11):783.
3	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
4	Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005-2009). Rev Iberoam Micol. 2009 Mar 31;26(1):15-22.
5	Clocortolone pivalate: a paired comparison clinical trial of a new topical steroid in eczema/atopic dermatitis. Cutis. 1980 Jan;25(1):96-8.
6	Utilization of epidermal phospholipase A2 inhibition to monitor topical steroid action. Br J Dermatol. 1984 Jul;111 Suppl 27:195-203.
7	Structures from powders: diflorasone diacetate. Steroids. 2009 Jan;74(1):102-11.
8	Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol. 1998 Jun;101(6 Pt 1):747-54.
9	Synthesis of benzoyl phenyl benzoates as effective inhibitors for phospholipase A2 and hyaluronidase enzymes. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4100-4.
10	Manoalide, a phospholipase A2 inhibitor, inhibits arachidonate incorporation and turnover in brain phospholipids of the awake rat. Neurochem Res. 1998 Oct;23(10):1251-7.
11	Phospholipase A2, group IVA (cytosolic, calcium-dependent) (PLA2G4A). SciBX 1(41); doi:10.1038/scibx.2008.999. Nov. 13 2008
12	A novel treatment of contact dermatitis by topical application of phospholipase A2 inhibitor: a double-blind placebo-controlled pilot study. Int J Immunopathol Pharmacol. 2007 Jan-Mar;20(1):191-5.